Cancer Genetics EV/EBITDA

Que fait Cancer Genetics ? Cancer Genetics Inc (CGI) is a biotechnology company that has been active in genetic cancer research since 1999. The company is headquartered in Rutherford, New Jersey, USA and is listed on NASDAQ under the abbreviation CGIX. It is involved in the development of diagnostic tests and procedures for identifying genetic mutations associated with various types of cancer. The history of CGI began with the founding of the company under the name NeoGenomics. The company was initially established in Florida and operated under this name until a realignment took place in 2000, focusing primarily on cancer diagnostics and prognosis. A year later, the company was renamed Cancer Genetics Inc when it relocated its headquarters to Rutherford, New Jersey. CGI's business model is based on the creation of diagnostic tests and services in the field of cancer early detection and prognosis, targeting the genetic basis of cancer. The company focuses on identifying changes in the DNA, RNA, and proteins of cancer cells, enabling predictions about tumor behavior and patient response to specific treatments. CGI's portfolio includes four business areas: Clinical Services, Pharma Services, Discovery Services, and BioPharma. In the clinical services area, the company offers several services, including diagnostic tests, sample analysis, and pathology tests. These include CGH microarray for identifying DNA changes, FISH test for identifying specific tumor driver mutations, as well as immunohistochemistry and molecular diagnostics. Secondly, in the Pharma Services business, the company provides a range of services related to clinical trials. This includes sample management, biomarker identification, and laboratory-based services such as patient recruitment and profiling, as well as the development of protocols and criteria for participation in clinical trials. The third area, Discovery Services, offers support to companies in preclinical research. This includes the identification and validation of biomarkers and target molecules that can be used in the research and development of new therapies and drugs for cancer. Lastly, the BioPharma division offers services related to partnerships in the development of oncology products. This involves collaborations with larger pharmaceutical companies where the company assists in the identification and conduct of clinical trials, as well as the development of diagnostic tests and personalized medications for the treatment of cancer. CGI also has a variety of products in the medical field, including a range of diagnostic tests, such as the Tissue of Origin® test for identifying the origin of cancer cells under given circumstances, OncoGenius® and FISHpath for identifying oncogenic triggers in cancer cells, and TargetSNP™, a genetic test for identifying polymorphisms associated with responsiveness to certain cancer drugs. Summary CGI is a publicly traded biotechnology company specializing in the development of diagnostic tests and procedures for identifying genetic mutations associated with various types of cancer. The company offers services in different areas of cancer research, from clinical diagnostics to partnerships in the development of cancer drugs. The CGI product portfolio includes a variety of diagnostic tests for identifying cancer triggers. The company aims to become a major player in cancer research and contribute significantly to the development of new and effective treatments for cancer patients. Cancer Genetics est l'une des entreprises les plus populaires sur Eulerpool.